ES2885080T3 - Composición inyectable que comprende fibroblastos para su utilización en el tratamiento de cardiopatías - Google Patents
Composición inyectable que comprende fibroblastos para su utilización en el tratamiento de cardiopatías Download PDFInfo
- Publication number
- ES2885080T3 ES2885080T3 ES18758465T ES18758465T ES2885080T3 ES 2885080 T3 ES2885080 T3 ES 2885080T3 ES 18758465 T ES18758465 T ES 18758465T ES 18758465 T ES18758465 T ES 18758465T ES 2885080 T3 ES2885080 T3 ES 2885080T3
- Authority
- ES
- Spain
- Prior art keywords
- fibroblasts
- cells
- human
- less
- positive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 286
- 239000007972 injectable composition Substances 0.000 title claims abstract description 44
- 208000019622 heart disease Diseases 0.000 title description 12
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims abstract description 221
- 206010019280 Heart failures Diseases 0.000 claims abstract description 43
- 210000005003 heart tissue Anatomy 0.000 claims abstract description 16
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 16
- 210000004351 coronary vessel Anatomy 0.000 claims abstract description 13
- 230000001338 necrotic effect Effects 0.000 claims abstract description 13
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 160
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 42
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 42
- 102000001045 Connexin 43 Human genes 0.000 claims description 13
- 108010069241 Connexin 43 Proteins 0.000 claims description 13
- 241000700159 Rattus Species 0.000 description 78
- 230000002861 ventricular Effects 0.000 description 62
- 238000000034 method Methods 0.000 description 42
- 230000004217 heart function Effects 0.000 description 38
- 206010007558 Cardiac failure chronic Diseases 0.000 description 37
- 210000002216 heart Anatomy 0.000 description 33
- 210000001054 cardiac fibroblast Anatomy 0.000 description 23
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 210000004413 cardiac myocyte Anatomy 0.000 description 21
- 230000006872 improvement Effects 0.000 description 21
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 206010061216 Infarction Diseases 0.000 description 17
- 230000007574 infarction Effects 0.000 description 17
- 230000003176 fibrotic effect Effects 0.000 description 16
- 238000012216 screening Methods 0.000 description 16
- 210000005240 left ventricle Anatomy 0.000 description 14
- 238000004904 shortening Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 206010002091 Anaesthesia Diseases 0.000 description 13
- 230000037005 anaesthesia Effects 0.000 description 13
- 230000000747 cardiac effect Effects 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000002592 echocardiography Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 10
- 210000000038 chest Anatomy 0.000 description 10
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 10
- 210000004165 myocardium Anatomy 0.000 description 10
- 238000011084 recovery Methods 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 239000004698 Polyethylene Substances 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000003125 immunofluorescent labeling Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000002107 myocardial effect Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000002595 magnetic resonance imaging Methods 0.000 description 6
- 230000003205 diastolic effect Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- 101150086694 SLC22A3 gene Proteins 0.000 description 4
- 102000013127 Vimentin Human genes 0.000 description 4
- 108010065472 Vimentin Proteins 0.000 description 4
- 210000002458 fetal heart Anatomy 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 102000034287 fluorescent proteins Human genes 0.000 description 4
- 108091006047 fluorescent proteins Proteins 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 238000007898 magnetic cell sorting Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- ALZOLUNSQWINIR-UHFFFAOYSA-N quinmerac Chemical compound OC(=O)C1=C(Cl)C=CC2=CC(C)=CN=C21 ALZOLUNSQWINIR-UHFFFAOYSA-N 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 210000005048 vimentin Anatomy 0.000 description 4
- 102000010970 Connexin Human genes 0.000 description 3
- 108050001175 Connexin Proteins 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000027902 cell growth involved in cardiac muscle cell development Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000002064 heart cell Anatomy 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000000651 myofibroblast Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 208000003663 ventricular fibrillation Diseases 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- -1 HFDM-1(+) Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 206010024119 Left ventricular failure Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001745 anti-biotin effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 description 2
- 210000003976 gap junction Anatomy 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000013842 nitrous oxide Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000011816 wild-type C57Bl6 mouse Methods 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004882 medetomidine hydrochloride Drugs 0.000 description 1
- VPNGEIHDPSLNMU-UHFFFAOYSA-N medetomidine hydrochloride Chemical compound Cl.C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 VPNGEIHDPSLNMU-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000010244 region-of-interest analysis Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 102000035087 single-pass transmembrane proteins Human genes 0.000 description 1
- 108091005496 single-pass transmembrane proteins Proteins 0.000 description 1
- 210000004683 skeletal myoblast Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017033624 | 2017-02-24 | ||
| PCT/JP2018/006795 WO2018155651A1 (ja) | 2017-02-24 | 2018-02-23 | 線維芽細胞を含む心臓疾患を治療するための注射用組成物、及び治療用線維芽細胞の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2885080T3 true ES2885080T3 (es) | 2021-12-13 |
Family
ID=63253929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18758465T Active ES2885080T3 (es) | 2017-02-24 | 2018-02-23 | Composición inyectable que comprende fibroblastos para su utilización en el tratamiento de cardiopatías |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11096969B2 (zh) |
| EP (1) | EP3476395B1 (zh) |
| JP (2) | JP6618066B2 (zh) |
| KR (1) | KR102407387B1 (zh) |
| CN (1) | CN109890398B (zh) |
| AU (1) | AU2018223739B2 (zh) |
| CA (1) | CA3032654A1 (zh) |
| DK (1) | DK3476395T3 (zh) |
| ES (1) | ES2885080T3 (zh) |
| IL (1) | IL267958B2 (zh) |
| SG (1) | SG11201900810WA (zh) |
| WO (1) | WO2018155651A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112639082A (zh) | 2018-08-29 | 2021-04-09 | 玛土撤拉有限公司 | 成纤维细胞的制备方法及g-csf阳性成纤维细胞群 |
| CN109589337B (zh) * | 2018-12-29 | 2022-04-26 | 南京艾尔普再生医学科技有限公司 | 心肌细胞制剂及其制备方法和应用 |
| AU2021230209A1 (en) * | 2020-03-04 | 2022-09-29 | Metcela Inc. | Fibroblast having enhanced erythropoietin production ability |
| EP4249585A1 (en) * | 2022-03-25 | 2023-09-27 | Technische Universität München - TUM | Heart tissue models, method of producing heart tissue models and uses of heart tissue models |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003901668A0 (en) * | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
| CN100435882C (zh) * | 2002-05-08 | 2008-11-26 | 加利福尼亚大学董事会 | 用成纤维细胞治疗心律失常的系统和方法 |
| US20040002740A1 (en) * | 2002-05-08 | 2004-01-01 | The Regents Of The University Of California | System and method for forming a non-ablative cardiac conduction block |
| US20040161412A1 (en) * | 2002-08-22 | 2004-08-19 | The Cleveland Clinic Foundation | Cell-based VEGF delivery |
| US7470538B2 (en) * | 2002-12-05 | 2008-12-30 | Case Western Reserve University | Cell-based therapies for ischemia |
| WO2005046447A2 (en) * | 2003-11-10 | 2005-05-26 | Symphony Medical, Inc. | Method to control ventricular rate in atrial fibrillation patients |
| US8513011B2 (en) * | 2004-08-26 | 2013-08-20 | Biotech Research Ventures Pte Limited | Methods and compositions for culturing cardiomyocyte-like cells |
| ES2325715B1 (es) * | 2007-08-03 | 2010-06-17 | Genetrix, S.L. | Poblacion de celulas madre adultas derivadas de tejido adiposo cardiaco y su uso en regeneracion cardiaca. |
| JP5378743B2 (ja) | 2008-09-30 | 2013-12-25 | テルモ株式会社 | 医療用細胞シートの製造方法 |
| WO2013028968A1 (en) * | 2011-08-25 | 2013-02-28 | Wisconsin Alumni Research Foundation | 3-dimensional cardiac fibroblast derived extracellular matrix |
| WO2013137491A1 (ja) | 2012-03-15 | 2013-09-19 | 国立大学法人京都大学 | 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法 |
| WO2014039995A1 (en) * | 2012-09-07 | 2014-03-13 | Fibrocell Technologies, Inc. | Fibroblast compositions for treating cardial damage after an infarct |
| GB201309057D0 (en) * | 2013-05-20 | 2013-07-03 | Cell Therapy Ltd | Method |
| KR20150009655A (ko) * | 2013-07-16 | 2015-01-27 | 학교법인 동아학숙 | Gcp-2 유전자를 과발현하는 지방 간엽줄기세포를 포함하는 허혈성 질환 치료용 조성물 |
| CA2954743C (en) * | 2014-07-11 | 2022-03-15 | Metcela Inc. | Cardiac cell culture material |
-
2018
- 2018-02-23 KR KR1020197003364A patent/KR102407387B1/ko active IP Right Grant
- 2018-02-23 DK DK18758465.1T patent/DK3476395T3/da active
- 2018-02-23 JP JP2019501845A patent/JP6618066B2/ja active Active
- 2018-02-23 AU AU2018223739A patent/AU2018223739B2/en active Active
- 2018-02-23 CN CN201880003050.1A patent/CN109890398B/zh active Active
- 2018-02-23 CA CA3032654A patent/CA3032654A1/en active Pending
- 2018-02-23 WO PCT/JP2018/006795 patent/WO2018155651A1/ja unknown
- 2018-02-23 ES ES18758465T patent/ES2885080T3/es active Active
- 2018-02-23 SG SG11201900810WA patent/SG11201900810WA/en unknown
- 2018-02-23 EP EP18758465.1A patent/EP3476395B1/en active Active
-
2019
- 2019-01-31 US US16/263,321 patent/US11096969B2/en active Active
- 2019-07-09 IL IL267958A patent/IL267958B2/en unknown
- 2019-10-03 JP JP2019182761A patent/JP7072135B2/ja active Active
-
2021
- 2021-07-19 US US17/379,671 patent/US20210346436A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102407387B1 (ko) | 2022-06-10 |
| US11096969B2 (en) | 2021-08-24 |
| CN109890398B (zh) | 2024-01-16 |
| JPWO2018155651A1 (ja) | 2019-11-07 |
| EP3476395B1 (en) | 2021-07-21 |
| US20190224250A1 (en) | 2019-07-25 |
| IL267958B2 (en) | 2023-08-01 |
| EP3476395A4 (en) | 2020-02-26 |
| IL267958B1 (en) | 2023-04-01 |
| DK3476395T3 (da) | 2021-08-16 |
| AU2018223739B2 (en) | 2023-06-22 |
| JP2019218408A (ja) | 2019-12-26 |
| SG11201900810WA (en) | 2019-02-27 |
| JP7072135B2 (ja) | 2022-05-20 |
| US20210346436A1 (en) | 2021-11-11 |
| CN109890398A (zh) | 2019-06-14 |
| EP3476395A1 (en) | 2019-05-01 |
| WO2018155651A1 (ja) | 2018-08-30 |
| KR20190117468A (ko) | 2019-10-16 |
| AU2018223739A1 (en) | 2019-02-14 |
| IL267958A (en) | 2019-09-26 |
| JP6618066B2 (ja) | 2019-12-11 |
| CA3032654A1 (en) | 2018-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2885080T3 (es) | Composición inyectable que comprende fibroblastos para su utilización en el tratamiento de cardiopatías | |
| Bao et al. | C-Kit Positive cardiac stem cells and bone marrow–derived mesenchymal stem cells synergistically enhance angiogenesis and improve cardiac function after myocardial infarction in a paracrine manner | |
| US10639335B2 (en) | Pluripotent stem cell that induces repair and regeneration after myocardial infarction | |
| Zhang et al. | Enhancing efficacy of stem cell transplantation to the heart with a PEGylated fibrin biomatrix | |
| JP6796143B2 (ja) | トロンビン処理幹細胞に由来するエキソソームを含む慢性肺疾患治療用組成物 | |
| Huang et al. | A translational approach in using cell sheet fragments of autologous bone marrow-derived mesenchymal stem cells for cellular cardiomyoplasty in a porcine model | |
| JP7428389B2 (ja) | 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団 | |
| US20200085875A1 (en) | Platelet vesicle-engineered cells for targeted tissue repair | |
| JP7091427B2 (ja) | 心不全の治療方法 | |
| BR112015008745B1 (pt) | Uso de um peptídeo de fragmento de hmgb1 para a fabricação de um medicamento para o tratamento de lesão do cordão espinhal | |
| EP3494979A1 (en) | Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells | |
| Fatkhudinov et al. | Bone Marrow‐Derived Multipotent Stromal Cells Promote Myocardial Fibrosis and Reverse Remodeling of the Left Ventricle | |
| JP5894071B2 (ja) | 心臓組織由来細胞 | |
| US20220347346A1 (en) | Mesenchymal stem cell sheet and use thereof | |
| WO2017012226A1 (zh) | 间质干细胞、其克隆源性扩增的方法、其分离方法及其应用 | |
| JPWO2004100972A1 (ja) | 組織破壊を伴う疾患の予防及び／または治療剤 | |
| ES2623142T3 (es) | Un método para amplificar las células madre cardíacas in vitro e in vivo | |
| Guo et al. | Young human PRP promotes the rejuvenation of aged bone marrow mesenchymal stem cells and the therapeutic effect on ischemic heart disease | |
| Kinugawa et al. | Safety and Efficacy of Autologous Skeletal Myoblast Sheets (TCD-5 1073) for the Treatment of Severe Chronic Heart |